NO20053986L - Sammensetninger og fremgangsmater for a behandle cancer anvendende IGSF9 og LIV-1. - Google Patents

Sammensetninger og fremgangsmater for a behandle cancer anvendende IGSF9 og LIV-1.

Info

Publication number
NO20053986L
NO20053986L NO20053986A NO20053986A NO20053986L NO 20053986 L NO20053986 L NO 20053986L NO 20053986 A NO20053986 A NO 20053986A NO 20053986 A NO20053986 A NO 20053986A NO 20053986 L NO20053986 L NO 20053986L
Authority
NO
Norway
Prior art keywords
polypeptides
igsf9
liv
methods
compositions
Prior art date
Application number
NO20053986A
Other languages
English (en)
Other versions
NO20053986D0 (no
Inventor
Robert J Peach
Karen Mclachlan
Scott Glaser
Tony Rowe
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of NO20053986D0 publication Critical patent/NO20053986D0/no
Publication of NO20053986L publication Critical patent/NO20053986L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

S a m m e n d r a g Humane IGSF9 og LIV- I polypeptider og DNA (RNA) som koder for slike polypeptider er redegjort for. De beskrevne polypeptidene og/eller polynukleotidene er spesielt anvendelige i å danne antistoffer, både modifiserte og native, som binder seg til IGSF9 eller LIV- l. Også redegjort for er farmasøytiske sammensetninger og vaksiner som består av antistoffene, polypeptidene og polynukleotidene tilhørende oppfinnelsen. Også redegjort for er metoder for å benytte slike polypeptider for å identifisere ligander, antagonister og agonister til nevnte polypeptider. Endelig er metodene, som omfatter de ovenfor nevnte sammensetningene redegjort for, hva gjelder behandling, diagnose, og/eller prognose av neoplastiske forstyrrelser.
NO20053986A 2003-01-27 2005-08-26 Sammensetninger og fremgangsmater for a behandle cancer anvendende IGSF9 og LIV-1. NO20053986L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44253503P 2003-01-27 2003-01-27
PCT/US2004/002044 WO2004066933A2 (en) 2003-01-27 2004-01-27 Compositions and methods for treating cancer using igsf9 and liv-1

Publications (2)

Publication Number Publication Date
NO20053986D0 NO20053986D0 (no) 2005-08-26
NO20053986L true NO20053986L (no) 2005-10-27

Family

ID=32825236

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053986A NO20053986L (no) 2003-01-27 2005-08-26 Sammensetninger og fremgangsmater for a behandle cancer anvendende IGSF9 og LIV-1.

Country Status (16)

Country Link
US (2) US20040258616A1 (no)
EP (1) EP1596806A4 (no)
JP (1) JP2006520194A (no)
KR (1) KR20050102627A (no)
CN (1) CN1849337A (no)
AU (1) AU2004207538A1 (no)
BR (1) BRPI0407031A (no)
CA (1) CA2514062A1 (no)
EA (1) EA200501197A1 (no)
IS (1) IS7960A (no)
MX (1) MXPA05007940A (no)
NO (1) NO20053986L (no)
PL (1) PL379264A1 (no)
RS (1) RS20050577A (no)
WO (1) WO2004066933A2 (no)
ZA (1) ZA200506671B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040141983A1 (en) * 1999-03-15 2004-07-22 Protein Design Labs, Inc. Compositions against cancer antigen LIV-1 and uses thereof
WO2004067564A2 (en) * 2003-01-29 2004-08-12 Protein Design Labs, Inc. Compositions against cancer antigen liv-1 and uses thereof
JPWO2005063301A1 (ja) * 2003-12-26 2007-07-19 平野　俊夫 Ｅｍｔ誘導剤
WO2006014999A2 (en) * 2004-07-27 2006-02-09 Five Prime Therapeutics, Inc. Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease
CN101622273A (zh) * 2006-04-13 2010-01-06 诺瓦提斯疫苗和诊断公司 治疗、诊断或检测与liv-1过量表达相关的癌症的方法
KR20110091423A (ko) * 2010-02-05 2011-08-11 국립암센터 항―ｔｍａｐ／ｃｋａｐ２ 항체를 포함하는 암의 예후 진단용 조성물
JP6105481B2 (ja) 2010-12-06 2017-03-29 シアトル ジェネティクス，インコーポレーテッド Ｌｉｖ−１に対するヒト化抗体および癌治療のためのその使用
MA45324A (fr) 2016-03-15 2019-01-23 Seattle Genetics Inc Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
CN110730787B (zh) * 2017-05-09 2023-11-03 辛利斯生物制药有限责任公司 修饰的微囊藻毒素和节球藻毒素
CN110563845A (zh) * 2019-09-12 2019-12-13 滨州医学院 抗igsf9抗体、药物组合物及其应用
KR20210122185A (ko) * 2020-03-31 2021-10-08 웰마커바이오 주식회사 Igsf1에 대한 항체를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물 및 이를 이용한 암 치료 방법
CN116082503B (zh) * 2022-08-19 2023-08-04 滨州医学院 一种靶向人igsf9的单克隆抗体及其应用
WO2024109944A1 (zh) * 2022-11-25 2024-05-30 江苏恒瑞医药股份有限公司 抗liv-1抗体、其药物偶联物及其医药用途
CN117379561B (zh) * 2023-10-13 2025-07-22 滨州医学院 一种靶向人igsf9的抗体偶联药物及其制备方法与应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) * 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5567610A (en) * 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4831175A (en) * 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5246692A (en) * 1986-09-05 1993-09-21 The United States Of America As Represented By The Secretary Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5099069A (en) * 1986-09-05 1992-03-24 Gansow Otto A Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5892019A (en) * 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) * 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5460785A (en) * 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690934A3 (en) * 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5124471A (en) * 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
US5229275A (en) * 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) * 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5756096A (en) * 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DE669986T1 (de) * 1992-11-13 1996-10-10 Idec Pharma Corp Völlig unfunktionelle konsensus-kozak-sequenzen zur säugetier-exprimierung.
US5648267A (en) * 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
MD1367C2 (ro) * 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
CA2132500A1 (en) * 1994-09-20 1996-03-21 David Lockwood Manning Methods for predicting the behaviour of breast tumours
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
GB9524973D0 (en) * 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
IL150592A0 (en) * 2000-01-25 2003-02-12 Genentech Inc Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer
AU2001290548A1 (en) * 2000-09-11 2002-03-26 Hyseq, Inc. Novel nucleic acids and polypeptides

Also Published As

Publication number Publication date
AU2004207538A1 (en) 2004-08-12
PL379264A1 (pl) 2006-08-07
US20040258616A1 (en) 2004-12-23
NO20053986D0 (no) 2005-08-26
BRPI0407031A (pt) 2006-01-17
IS7960A (is) 2005-07-27
WO2004066933A3 (en) 2006-03-02
RS20050577A (sr) 2007-09-21
CN1849337A (zh) 2006-10-18
US20070071674A1 (en) 2007-03-29
CA2514062A1 (en) 2004-08-12
EP1596806A2 (en) 2005-11-23
WO2004066933A2 (en) 2004-08-12
EP1596806A4 (en) 2007-08-29
EA200501197A1 (ru) 2006-04-28
ZA200506671B (en) 2006-09-27
KR20050102627A (ko) 2005-10-26
JP2006520194A (ja) 2006-09-07
MXPA05007940A (es) 2007-06-14

Similar Documents

Publication Publication Date Title
NO20053986L (no) Sammensetninger og fremgangsmater for a behandle cancer anvendende IGSF9 og LIV-1.
WO2003034903A3 (en) Psma antibodies and protein multimers
NO347649B1 (no) Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
ATE455127T1 (de) Humane anti-humane cd3-bindungsmoleküle
CY1118977T1 (el) Επιτοποι σκληροστινης
CY1118979T1 (el) Αντισωματα που κατευθυνονται εναντι her-3 και χρησεις αυτων
HUP0401591A2 (hu) Új receptor-nukleinsavak és- polipeptidek
MX353319B (es) Composiciones y metodos relacionados con anticuerpos del receptor de glucagon.
MX2022015847A (es) Proteinas de union a cd123 y composiciones y metodos relacionados.
EA200901436A1 (ru) Антигенсвязывающие белки, связывающие par-2
DE60028970D1 (de) An her2 bindende peptidverbindungen
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
NO20083053L (no) Humane monoklonale antistoffer mot O8E
NO20091736L (no) IL-17-reseptor A-antigenbindende proteiner
SG144925A1 (en) Methods for treating cardiovascular disease using a soluble ctla4 molecule
WO2006040129A3 (de) Ubiquittin oder gamma-kristallin-konjugate zur verwendung in therapie, diagnose und chromatographie
WO2005056600A3 (en) Monoclonal antibodies that bind or neutralize dengue virus
WO2003076592A3 (en) Novel method for delivery and intracellular synthesis of sirna molecules
WO2003013534A3 (en) Methods for the treatment of cancer with irinotecan based on cyp3a5
FI20011671A7 (fi) Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö
DK1844072T3 (da) MHC-oligomer og fremgangsmåde til fremstilling deraf
WO2004055513A3 (en) Use of cd137 antagonists for the treatment of tumors
WO2004094476A3 (en) Compositions and methods relating to stop-1
EP2287194A3 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
WO2004051269A3 (en) Ciz1 replication protein

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application